Document is current
Any future updates will be listed below
-
Authors
Chen, Binbin
Khodadoust, Michael S.
Olsson, Niclas https://orcid.org/0000-0002-9746-0542
Wagar, Lisa E.
Fast, Ethan
Liu, Chih Long
Muftuoglu, Yagmur
Sworder, Brian J.
Diehn, Maximilian https://orcid.org/0000-0003-2032-0581
Levy, Ronald
Davis, Mark M. https://orcid.org/0000-0001-6868-657X
Elias, Joshua E. https://orcid.org/0000-0002-8063-3259
Altman, Russ B.
Alizadeh, Ash A. https://orcid.org/0000-0002-5153-5625
-
Funding
Funding for this research was provided by:
SU | Stanford Bio-X
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K08 CA207882)
U.S. Department of Health & Human Services | NIH | U.S. National Library of Medicine (GM 102365)
- License Information
-
More Information
Article History
Received: 22 February 2019
Accepted: 9 September 2019
First Online: 14 October 2019
Competing interests
: A.A.A. declares the following competing interests: stock or other ownership (CiberMed and Forty Seven); honoraria (Janssen Oncology); consulting or advisory roles (Celgene, Roche/Genentech and Gilead Sciences); research funding (Celgene); patents, royalties or other intellectual property (patent filings on immune deconvolution and circulating tumor DNA detection assigned to Stanford University); and travel, accommodations or expenses (Roche and Gilead Sciences). R.B.A. declares the following competing interests: stock or other ownership (Personalis); consulting or advisory role (Pfizer, Youscript, 23andme and WithHealth); patents, royalties or other intellectual property (royalties for patents related to genome sequencing).
